Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Extensive Stage Lung Small Cell Carcinoma 1

Interventions

fludarabine phosphate 18 Whole-Body Irradiation 12 Peripheral Blood Stem Cell Transplantation 12 Mycophenolic Acid 11 ruxolitinib 10 Busulfan 10 Tacrolimus 9 Cyclophosphamide 9 fludarabine 6 Methotrexate 5 Melphalan 5 Cyclosporine 5 Hydroxyurea 4 Antilymphocyte Serum 4 pomalidomide 3 givinostat hydrochloride 3 givinostat 3 Stem Cell Transplantation 3 Prednisone 3 Lenalidomide 3 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3 thymoglobulin 2 peginterferon alfa-2a 2 merphos 2 Surveys and Questionnaires 2 Radiotherapy 2 Imatinib Mesylate 2 Etoposide 2 Dasatinib 2 Carboplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Polycythemia Vera × bomedemstat × Clear all

NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed

20 enrolled 19 charts

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon ⚡